Despite Wall Street's harsh reaction to Esperion Inc.'s second, successful phase III trial with bempedoic acid (BA) in dropping low-density lipoprotein cholesterol (LDL-C), analysts found the data salutary in the big picture and supportive of approval. "All in all, there are some positives here and it's good enough to cross the bar in our view, but also [there are] some issues [that] the bears will try to harp on vs. 'expectations,' which is what is impacting the stock," wrote Jefferies' Michael Yee in a report.